DDInter501 DDInter105
Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical procedures.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Deoxycholic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetylsalicylic acid
Deoxycholic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib